tbuckley/cabot-search huggingface dataset:
Economic evidence for nonpharmacological asthma management interventions: A systematic review
Authors: C‐J. Crossman‐Barnes, A. Peel, R. Fong‐Soe‐Khioe, T. Sach, A. Wilson, G. Barton
Journal: Allergy (2017)

Asthma management, education and environmental interventions have been reported as cost-effective in a previous review (Pharm Pract (Granada), 2014;12:493), but methods used to estimate costs and outcomes were not discussed in detail. This review updates the previous review by providing economic evidence on the cost-effectiveness of studies identified after 2012, and a detailed assessment of the methods used in all identified studies. Twelve databases were searched from 1990 to January 2016, and studies included economic evaluations, asthma subjects and nonpharmacological interventions written in English. Sixty-four studies were included. Of these, 15 were found in addition to the earlier review; 53% were rated fair in quality and 47% high. Education and self-management interventions were the most cost-effective, in line with the earlier review. Self-reporting was the most common method used to gather resource-use data, accompanied by bottom-up approaches to estimate costs. Main outcome measures were asthma-related hospitalizations (69%), quality of life (41%) and utility (38%), with AQLQ and the EQ-5D being the most common questionnaires measured prospectively at fixed time points. More rigorous costing methods are needed with a more common quality of life tool to aid greater replicability and comparability amongst asthma studies.
HOUT-01. CUMULATIVE SCORE BASED ON PRETREATMENT NEUTROPHIL TO LYMPHOCYTE RATIO AND ALBUMIN TO GAMMA-GLUTAMYLTRANSFERASE RATIO AS A NOVEL PREDICTOR FOR WHO GRADE III GLIOMA PATIENTS
Authors: Zhenqiang He, Xiaobing Jiang, Yong Gao Mou
Journal: Neuro-Oncology (2017)

Preoperative systemic inflammation response was reported to have prognostic significance in cancer patients. We aim to evaluate different systemic inflammation-based indexes, including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), albumin to gamma-glutamyltransferase ratio (AGR) and C-reactive protein to albumin ratio (CRP/Alb), in newly diagnosed high-grade glioma (HGG) patients. 322 newly diagnosed HGG patients (World Health Organization Grade III=154, Grade IV=168) were retrospectively reviewed in our study. Cut-off values of inflammation-based indexes are determined by receiver operating characteristic (ROC) analysis or median values. Univariate and multivariate were applied to evaluate the prognostic significance. At the date of the last follow-up, 252 (78.0%) patients had died. Median OS of patients with WHO Grade III and IV patients was 25.53 (95% CI 17.00-34.06) months and 14.30 (95% CI 12.04-16.56) months, respectively. Kaplan-Meier analysis showed that high levels of NLR, PLR and low level of AGR can significantly predict worse PFS and OS in WHO Grade III glioma patients. While no inflammation-based index in our study showed prognostic value in WHO Grade IV patients. Multivariate analysis further identified cumulative score combining NLR and AGR as an independent predictor of both PFS (P=0.001) and OS (P=0.001) in WHO Grade III glioma patients after adjusting for demographic and clinical covariates. The novel cumulative score based on pretreatment NLR and AGR can be a promising predictor of survival for the patients with WHO Grade III gliomas.
P1.02-038 Bilateral Combined Lymphangioleiomyomatosis and Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia with Typical Carcinoids
Authors: J. Von Der Thüsen, P. Atmodimedjo, E. Dubbink, J. Miedema, W. Dinjens
Journal: Journal of Thoracic Oncology (2017)
Dos brotes de sarampión en Alemania, 2005
Authors: A Siedler, A Tischer, A Mankertz, S Santibanez
Journal: Eurosurveillance (2006)

En Alemania, hay comunidades donde el sarampion re-emergio en 2005, a pesar del aumento, en los ultimos anos, de la cobertura vacunal en los ninos que entran en la escuela, lo que permitio una disminucion de la incidencia (0,2 casos por 100.000 en 2004, la incidencia mas baja jamas declarada). 
En los estados de Hesse y de Baviera se detectaron brotes regionales de sarampion a traves del sistema de notificacion obligatoria. Las incidencias fueron semejantes en los brotes de las dos areas afectadas (14 y 12 casos por 100.000, respectivamente), pero eran distintos en cuanto a la distribucion segun la edad, el modo de transmision y el genotipo viral. 
En el estado de Hesse, se analizaron 223 casos, de los cuales 160 pertenecian a 41 clusters, principalmente definidos por contacto familiar o en el hogar. La tasa de ataque mas alta era en ninos entre 1 y 4 anos (102 casos por 100.000). Los resultados del diagnostico viral muestran que todos los casos de Hesse analizados tenian el mismo genotipo D4 y secuencias nucleotidicas identicas. 
En Baviera, fueron declarados 279 casos, la mayoria de ellos en escuelas o centros preescolares. La tasa de ataque mas alta fue en ninos entre 5 y 9 anos (129 por 100.000). El genotipo viral D6 se identifico por diagnostico microbiologico. Las cepas tenian secuencias nucleotidicas identicas. 
En los dos brotes, la mayoria de los casos (el 95% en el estado de Hesse y el 98% en Baviera) eran ninos no vacunados, pero era diferente la cobertura vacunal segun la region, siendo un poco mas baja en Baviera. Antes de este brote, habia aumentado el numero de ninos no vacunados en Baviera, estando concentrados en escuelas y jardines de infancia. 
A pesar de un nivel medio alto de cobertura vacunal, las variaciones locales pueden dar lugar a brotes limitados regionalmente.
PALL-03. I-CoPE: A PILOT STUDY OF AN INNOVATIVE MODEL OF SUPPORTIVE AND PALLIATIVE CARE FOR PATIENTS WITH HIGH GRADE GLIOMA AND THEIR FAMILY CARERS
Authors: Jennifer Philip, Anna Collins
Journal: Neuro-Oncology (2017)

There is little evidence to guide supportive care delivery to patients with High Grade Glioma (HGG). An intervention, I-CoPE, provides Information, Coordination, Preparation and Emotional support for people newly diagnosed HGG and their family carers. Delivered by a cancer care coordinator, I-CoPE consists of (1) information staged according to illness stage, (2) regular screening for needs with responses instituted, (3) facilitation of information transfer and (4) family carer engagement. To pilot test acceptability and preliminary effectiveness of I-CoPE delivered over three transitions in the illness course (following diagnosis, following diagnostic hospitalisation, following radiotherapy), for people newly diagnosed with HGG and their carers. I-CoPe was delivered at the identified transition points, with data collection following transitions at enrolment, 2 weeks and 12 weeks. Outcomes of interest included: acceptability (primary); quality of life [patient (FACT-Br), carer (CQOLC)]; needs for support [patient (SCNS-SF34), carer (CNSAT)]; disease-related information needs (PINQ); and preparedness to care [carer (PCS)] (secondary). Descriptive statistics were used to assess acceptability outcomes. Differences in patient and carer outcomes before and after ICoPE were assessed using repeated measures ANOVA. Thirty two patients (53% male, mean age 60), and 31 carers (42% male) participated. I-CoPE was highly acceptable: 95% eligible patients enrolled, 27 (88%) contributing data until deterioration/death. Post I-cope: (1) Patients reported fewer information (p<.001, ƞp2 .33) needs and improvements in quality of life following their diagnostic hospitalisation (p<.003, ƞp2 .24), which were not sustained following radiotherapy. (2) Carers reported fewer unmet supportive care (p=.009, ƞp2 .21) and information needs (p<.001, ƞp2 .33), improved quality of life (p=.08, ƞp2 .11), and increased preparedness to care (p=.04, ƞp2 .13). A model of supportive care delivered based upon illness transitions is highly acceptable and suggests preliminary efficacy in some areas. Formal randomized studies are now required.
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib
Authors: Jin Kang, Hua-Jun Chen, Zheng Wang, Jing Liu, Bing Li, Tengfei Zhang, Zhenfan Yang, Yi-Long Wu, Jin-Ji Yang
Journal: Journal of Thoracic Oncology (2017)

The efficacy of crizotinib, an adenosine triphosphate–competitive, type I mesenchymal-epithelial transition (MET) inhibitor, was compromised by the development of acquired secondary-site mutations such as MNNG HOS Transforming gene (MET) D1228N/H/V and Y1230H.1–4 Type II inhibitors, such as cabozantinib, bind to an inactive conformation of MET, inhibiting a broader array of kinase targets.5 A limited number of studies have reported MET inhibitor–associated resistance. In this study, we have described a patient with EGFR-mutant lung adenocarcinoma clinically benefitting from combinatorial therapy of osimertinib and cabozantinib after simultaneous development of four MET mutations upon crizotinib treatment.
P2.07-050 Impact of Steroid Use for Immune Related Adverse Events on Outcomes in Non-Small Cell Lung Cancer (NSCLC) Treated with Checkpoint Inhibitors
Authors: N. Shah, W. Kelly, B. Ma, J. Puthiamadathil, M. Serzan, Y. Zhou, M. Tan, D. Subramaniam, G. Giaccone, S. Liu
Journal: Journal of Thoracic Oncology (2017)
P3.03-006 Efficiency of Anlotinib as 3rd Line Treatment in Patients with Different EGFR Gene Status, an Exploratory Subgroup Analysis of ALTER0303 Trial
Authors: B. Han, K. Li, Q. Wang, Y. Zhao, L. Zhang, J. Shi, Z. Wang, Y. Cheng, J. He, S. Yuankai, W. Chen, X. Wang, Y. Luo, K. Nan, F. Jin, B. Li
Journal: Journal of Thoracic Oncology (2017)
Guías BICHAT para el manejo clínico de la viruela y de la viruela relacionada con el bioterrorismo
Authors: P Bossi, A Tegnell, A Baka, F van Loock, A Werner, J Hendriks, H Maidhof, G Gouvras
Journal: Eurosurveillance (2004)

La viruela es una infeccion virica debida al virus de la variola. En 1980, la OMS la declaro erradicada en todo el mundo tras una campana de erradicacion antivariolica. La viruela es uno de los virus con mayores probabilidades de ser utilizado como arma
P3.03-011 A Report of BRAF V600E Positive Lung Adenocarcinoma Patient Who Respond Well to Pemetrexed
Authors: Y. Nakagawa, Y. Nakanishi, I. Tsujino, T. Shimizu, N. Takahashi, Y. Kusumi, S. Masuda, S. Hashimoto
Journal: Journal of Thoracic Oncology (2017)
Existe-t-il « d’anciens » et de « nouveaux » modes de détection des risques et des épidémies de maladies infectieuses ?
Authors: J C Desenclos
Journal: Eurosurveillance (2006)

En mai 2005, l’Assemblee mondiale de la sante a approuve une revision innovante et ambitieuse du Reglement sanitaire international (RSI(2005)), afin de detecter et controler rapidement tous les evenements de sante publique susceptibles d’avoir un impact international important. Il s’agit d’une evolution majeure de la declaration administrative de cas d’une liste limitee de maladies par les Etats Membres (EM) a l’Organisation Mondiale de la Sante (OMS) a l’analyse systematique des evenements sanitaires de portee internationale, qu’ils soient ou non dans le champ infectieux [1]. L’analyse de ces evenements de sante publique prendra en compte la gravite de l’evenement, son aspect inattendu, le risque potentiel de propagation internationale, et les entraves aux voyages et aux echanges commerciaux internationaux. Des points focaux nationaux doivent etre identifies au sein de chaque EM pour interagir avec l’OMS. Le principe du nouveau RSI est de faciliter l’instauration rapide du dialogue entre Etats Membres (EM) et OMS, en vue d’une evaluation mutuelle rapide des risques decoulant d’evenements qui ne devront pas automatiquement etre declares, en fonction des resultats de l’evaluation et des mesures prises. L’OMS peut egalement utiliser des sources non officielles pour detecter plus rapidement des evenements de portee internationale et mettre alors en place, avec la collaboration du point focal national, la verification, l’evaluation des risques et les mesures appropriees.
P2.09-006 FISH Analysis of p16 and BAP1 Immunohistochemistry for the Diagnosis of Mesothelioma
Authors: K. Hiroshima, D. Wu, T. Yusa, D. Ozaki, E. Koh, Y. Sekine, R. Haba, K. Washimi, K. Nabeshima, T. Tsujimura
Journal: Journal of Thoracic Oncology (2017)
RTHP-36. CS 131 BRACHYTHERAPY FOR SALVAGE OF RECURRENT BRAIN TUMORS
Authors: Emad Youssef, Theresa Thomas, Peter Nakaji, Kris Smith, Nader Sanai, Heyoung McBride, Joseph Zabramski, Stephen Sorensen, Chris Dardis, David Brachman
Journal: Neuro-Oncology (2017)

Effective treatments for recurrent, previously irradiated intracranial neoplasms are limited. For this reason, we decided to study the combination of maximum safe resection and adjuvant radiation using permanent intracranial brachytherapy (S+BT) with implanted Cs -131 sources in modular carriers in this cohort of patients. Between 5/2013 and 11/2016 58 recurrent, previously irradiated tumors (High Grade Glioma 41%, Meningioma 40%, and Metastases 19%) in 55 patients (31 males and 24 females) were treated on a single arm Institutional Review Board (IRB) approved trial of surgery and permanent implanted brachytherapy (S+BT) utilizing Cs-131 sources imbedded in modular collagen carriers/spacers that were implanted in the operative bed at the completion of maximally safe resection. Radiation dose prescribed was 60-80 Gy at 5 mm deep to the operative bed. Kaplan-Meier analysis (Log rank tests) was used to model time to local tumor progression. All patients had previously undergone same site surgery (range of 1-4 craniotomies) and radiation therapy (range 1-3 courses). At a median follow-up for the whole group of 10.8 months and living patients of 10.95 months (N=29) respectively, twelve patients (20 %) had local recurrence at an average of 11.33 months (range 2.3-29.13 months) post implant. Six and 12 months local recurrence free survival is 91 % and 81 % respectively. Six and 12 months Progression Free Survival (PFS) (counting death and local recurrence as events) is 75 % and 61 % respectively. Five patients (11%) had Grade 3 or higher complications, with wound infection/dehiscence in 4 patients and 1 patient with radiation necrosis treated with laser ablation. Surgery and brachytherapy using Cs131seeds imbedded in modular carriers appears to be a safe and effective salvage therapy for patients with recurrent, previously irradiated intracranial tumors.
OA 18.04 Whole Genome Tumor-Normal Sequencing Reveals Potential False Positives Versus Standard CGP Sequencing in Patients with NSCLC
Authors: J.Z. Sanborn, S. Benz, C. Garner, P. Soon-Shiong, S. Rabizadeh, S. Reddy
Journal: Journal of Thoracic Oncology (2017)
Psychological stress and psoriasis: a systematic review and meta-analysis
Authors: I. Snast, O. Reiter, L. Atzmony, Y.A. Leshem, E. Hodak, D. Mimouni, L. Pavlovsky
Journal: British Journal of Dermatology (2017)

Psychological stress has long been linked with the exacerbation/onset of psoriasis. To determine if antecedent psychological stress is associated with the exacerbation/onset of psoriasis. A search of the PubMed, PsycINFO, Cochrane library and ClinicalTrials.gov databases was performed. Surveys evaluating beliefs about stress reactivity were analysed separately. Suitable studies were meta‐analysed. Thirty‐nine studies (32 537 patients) were included: 19 surveys, seven cross‐sectional studies, 12 case–control studies and one cohort study. Forty‐six per cent of patients believed their disease was stress reactive and 54% recalled preceding stressful events. Case–control studies evaluating stressful events rates prior to the exacerbation (n = 6) or onset (n = 6) of psoriasis varied in time lag to recollection (≤ 9 months to ≥ 5 years). Pooling five studies evaluating stressful events preceding onset of psoriasis gave an odds ratio (OR) of 3·4 [95% confidence interval (CI) 1·8–6·4; I2 = 87%]; the only study evaluating a documented stress disorder diagnosis reported similar rates between patients and controls (OR 1·2, 95% CI 0·8–1·8). Four studies evaluating stressful events prior to psoriasis exacerbation reported comparable rates with controls, whereas two found more frequent/severe preceding events among patients with psoriasis. A small prospective cohort study reported a modest association between stress levels and exacerbation of psoriasis (r = 0·28, P < 0·05). The association between preceding stress and exacerbation/onset of psoriasis is based primarily on retrospective studies with many limitations. No convincing evidence exists that preceding stress is strongly associated with exacerbation/onset of psoriasis.
Malignant pleural mesothelioma multidisciplinary team unit: experience of one high-volume center in Italy
Authors: L. Gianoncelli, V. Nava, L. Mazza, M. Bonomi, E. Cerchiaro, A. Zanello, C.N. De Filippis, M. Mazzoleni, L. Vernile, A. Ruello, J. Vargas, G. Beretta, L. Bortolotti, V. Vavassori, P. Maggioni, G.L. Ceresoli
Journal: Annals of Oncology (2017)
MA 14.01 Influence of Early Lung Cancer Screening Program on Treated Patients' Profile and Activity of Thoracic Surgery Department
Authors: M. Wojtyś, B. Kubisa, T. Grodzki, J. Pieróg, J. Wójcik, N. Wójcik, J. Alchimowicz, P. Waloszczyk
Journal: Journal of Thoracic Oncology (2017)
P1.04-008 POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
Authors: T. Mok, M. Johnson, E. Garon, S. Peters, J. Soria, L. Wang, A. Jarkowski, P. Dennis, C. Zhou
Journal: Journal of Thoracic Oncology (2017)
Can the salivary microRNA expression profile help to identify novel biomarkers for oral squamous cell carcinoma detection?
Authors: R. Maragliano, D. Fanale, L. Incorvaia, S. Caruso, N. Barraco, G. Badalamenti, S. Rizzo, V. Calò, A. Perez, A. Listì, A. Galvano, F. Passiglia, A. Guarini, E. Bronte, L. Insalaco, D. Massihnia, L. Castellana, F. Di Piazza, V. Bazan, A. Russo
Journal: Annals of Oncology (2017)
ACTR-36. A PHASE I STUDY OF NEURAL STEM CELLS LOADED WITH AN ONCOLYTIC ADENOVIRUS FOR PATIENTS WITH NEWLY DIAGNOSED MALIGNANT GLIOMA: PRELIMINARY SAFETY AND DATA ANALYSIS
Authors: Maciej S Lesniak, Roger Stupp, Sean Sachdev, Rimas Lukas, James Chandler, Jana Portnow, Christina Amidei, Jason Miska, Irina Balyasnikova, Atique Ahmed, David Curiel, Theresa Strong, Ann LeFever, Ann Adams, Francis Giles, Karen Aboody
Journal: Neuro-Oncology (2017)

Oncolytic virotherapy represents a potentially innovative approach for patients with malignant glioma. A major obstacle to effective therapy has been effective delivery of an oncolytic virus to the tumor. For this first-in-human phase I clinical study, we developed a novel oncolytic adenovirus, CRADd-Survivin-pk7, which utilizes the survivin promoter and binds to heparan sulfate proteoglycans expressed on the surface of tumor cells. Survivin is overexpressed in gliomas and is also a radiosensitive promoter driving viral replication in glioma but not normal brain cells. The virus was then loaded onto a neural stem cell line, HB1.F.CD, and a clinical grade agent was produced and approved by the FDA (IND 17365). The FDA approved the use of the clinical product in the initial setting, not recurrence, for patients with grade III and IV gliomas. This clinical trial consists of two cohorts, resectable and unresectable tumors, each with a classical 3 + 3 design. After biopsy or resection, increasing doses of virus loaded stem cells are injected. Cohort 1 consists of 50 million stem cells (6.25x1010 vp/patient), cohort 2 consists of 100 million stem cells (1.25x1011 vp/patient) and cohort 3 consists of 150 million stem cells (1.875x1011 vp/patient). Within 14 days, each patient then starts standard chemoradiotherapy (TMZ/RT). Safety and toxicity occurring until the end of TMZ/RT (day 56) is the primary endpoint, changes in cytokines and T-cells subgroups are correlative secondary endpoints. The first patient was treated in May 2017, and we will report on the first cohorts of patients at the meeting. Combining stem cells with oncolytic viruses may open up new avenues for effective delivery of gene therapy and oncolytic virotherapy to malignant brain tumors.
RTHP-07. TREATMENT OF BRAIN RADIATION NECROSIS WITH HYPERBARIC OXYGEN: REPORT OF 6 CASES
Authors: Mossaed Alyahya, Sivam Mittal, David Rowe, Mitch Machtay, Syed J Ali, Warren Selman, Andrew Sloan, Lisa Rogers
Journal: Neuro-Oncology (2017)

Cerebral radiation necrosis (CRN) is a delayed complication of brain radiotherapy. Treatment includes resection, steroids, bevacizumab, anticoagulation, and/or hyperbaric oxygen (HBO). There is little published information regarding efficacy of HBO for CRN. Retrospective review of patients treated with HBO for CRN at our institution. We identified six adults, four with brain tumor (BT) [GBM 1, grade 2 oligodendroglioma 1, grade 2 meningioma 1, anaplastic hemangiopericytoma 1] and two with AVM. BT patients were treated with external beam radiation in 3, 1 in combination with stereotactic radiosurgery (SRS), and 1 only with SRS. AVM patients were treated only with SRS. CRN without recurrent tumor was diagnosed at surgery in the glioma patients. CRN was diagnosed by MRI PET/perfusion in the 2 other BT patients. Surgery and advanced imaging were not deemed necessary in the AVM patients. Lesions of CRN were not resectable. Dexamethasone was ineffective in each patient and bevacizumab was ineffective in each of 2 patients. HBO was administered at 2 atmospheric pressures for 90 minutes, five days a week for 25 to 60 treatments. Best responses were partial response in 4 patients, maintained from 9 months to 5 years (glioma patients, AVM 1, meningioma 1) and stable disease in 1 AVM patient. Clinical decline occurred after 25 treatments in the hemangiopericytoma patients and HBO was discontinued. Significant and durable responses to HBO were noted in 4/6 patients with CRN. These results compare favorably with bevacizumab and merit additional study of HBO in CRN.
RTHP-13. EMERGENCY RADIOTHERAPY FOR PATIENTS WITH RAPIDLY DETERIORATING INTRACRANIAL GERM CELL TUMORS
Authors: Linbo Cai, Mingyao Lai, Juan Lee, Jiangfen Zhou, Changguo Shan, Weiping Hong
Journal: Neuro-Oncology (2017)

To retrospectively summarize the efficacy of emergency radiotherapy for critical patients with rapidly deteriorating intracranial germ cell tumors, and to evaluate the clinical value of emergency radiotherapy as salvage therapy. 20 patients with intracranial germ cell tumors were admitted from 2007 to 2016, including 16 males and 4 females with a median age of 16 years (range 10 to 26 years), 11 patients with germinoma and 9 patients with NGGCTs. All patients were treated with emergency radiotherapy with or without concurrent chemotherapy. Among them, 5 patients were treated with concurrent chemo-radiotherapy and 5 patients with NGGCTs were treated with stereotactic radiosurgery (SRS) for residual tumor after emergency radiotherapy. Twenty patients were followed up with a median follow-up time of 49 months (range 2 to 107 months). Nineteen patients could tolerate radiotherapy and had finished radiotherapy treatment, only one patient died. The remission rate was 95%. The GCS score of 15 patients was 15 after treatment, with KPS≥70 in 15 patients. At 1 month later after treatment, the efficacy evaluated by the MRI showed that 9 cases of CR, 2 cases of PR in 11 cases of germinomas, and 5 cases of PR, 3 cases of CR in 9 cases of NGGCTs. At the end of follow-up 5 cases died, and 15 cases survived. The 5-year overall survival rate is 74% (95%CI:0.456-0.874) for 11 patients with germinoma while is 65% (95%CI:0.404-0.834) for patients with NGGCTs. Emergency radiotherapy can be used as the salvage therapy for critical patients with rapidly deteriorating intracranial germ cell tumors because of its quick action. Emergency radiotherapy combined with concurrent chemotherapy and SRS for residual tumor can bring survival benefits for patients with intracranial germ cell tumors, however, it till requires further clinical research.